![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CADM3 |
Gene summary for CADM3 |
![]() |
Gene information | Species | Human | Gene symbol | CADM3 | Gene ID | 57863 |
Gene name | cell adhesion molecule 3 | |
Gene Alias | BIgR | |
Cytomap | 1q23.2 | |
Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q8N126 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57863 | CADM3 | P11T-E | Human | Esophagus | ESCC | 5.16e-10 | 1.07e+00 | 0.1426 |
57863 | CADM3 | P19T-E | Human | Esophagus | ESCC | 2.84e-04 | 7.37e-01 | 0.1662 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CADM3 | CADM3 | CADM3_CADM3 | CADM | GC | Precancer |
CADM3 | CADM3 | CADM3_CADM3 | CADM | HNSCC | ADJ |
CADM3 | CADM3 | CADM3_CADM3 | CADM | HNSCC | Healthy |
CADM3 | CADM3 | CADM3_CADM3 | CADM | Lung | ADJ |
NECTIN1 | CADM3 | NECTIN1_CADM3 | NECTIN | Prostate | BPH |
CADM3 | CADM3 | CADM3_CADM3 | CADM | Prostate | BPH |
NECTIN1 | CADM3 | NECTIN1_CADM3 | NECTIN | Prostate | Healthy |
CADM3 | CADM3 | CADM3_CADM3 | CADM | Prostate | Healthy |
CADM3 | CADM3 | CADM3_CADM3 | CADM | Prostate | Tumor |
NECTIN1 | CADM3 | NECTIN1_CADM3 | NECTIN | Skin | cSCC |
CADM3 | CADM3 | CADM3_CADM3 | CADM | Skin | cSCC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CADM3 | SNV | Missense_Mutation | novel | c.172G>T | p.Asp58Tyr | p.D58Y | Q8N126 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADM3 | SNV | Missense_Mutation | c.817N>T | p.Pro273Ser | p.P273S | Q8N126 | protein_coding | tolerated(0.15) | benign(0.066) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CADM3 | SNV | Missense_Mutation | c.1289N>G | p.Tyr430Cys | p.Y430C | Q8N126 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
CADM3 | SNV | Missense_Mutation | rs150071589 | c.136N>A | p.Asp46Asn | p.D46N | Q8N126 | protein_coding | deleterious_low_confidence(0.05) | benign(0.024) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADM3 | SNV | Missense_Mutation | c.716N>T | p.Ala239Val | p.A239V | Q8N126 | protein_coding | tolerated(1) | benign(0.014) | TCGA-EW-A1PG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
CADM3 | insertion | Frame_Shift_Ins | novel | c.483dupA | p.Gly162ArgfsTer12 | p.G162Rfs*12 | Q8N126 | protein_coding | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
CADM3 | insertion | Nonsense_Mutation | novel | c.484+1_484+2insGCCTTGACTGAAGGGAAGTTATTG | Q8N126 | protein_coding | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||||
CADM3 | insertion | Nonsense_Mutation | novel | c.695_696insCCACCCAATTGTGCTGTAAGTGGAGGGTCATATATCATGCCTGTGC | p.Thr233HisfsTer6 | p.T233Hfs*6 | Q8N126 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CADM3 | insertion | Frame_Shift_Ins | novel | c.1130_1131insC | p.Leu378AlafsTer23 | p.L378Afs*23 | Q8N126 | protein_coding | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
CADM3 | deletion | Frame_Shift_Del | novel | c.1132_1142delCTGCTCATCAT | p.Leu378AlafsTer19 | p.L378Afs*19 | Q8N126 | protein_coding | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |